Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Vanguard Health Care ETF (VHT) is rated a hold due to high valuations and low profitability of top holdings despite strong ...

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

Verve received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. Read more about ...

Impending U.S. tariffs could have a deep impact on the Irish economy and its strong reliance on pharmaceuticals and digital.